2011 Biosimilars and Follow-On Biologics Americas Conference: The Frost & Sullivan Perspective

 

Regular Price: USD 1,500

Special Price USD 1,050

30% OFF

* Required Fields

Regular Price: USD 1,500

Special Price USD 1,050

PAY BY INVOICE

Be the first to review this product

This research segment presents the key highlights from the 2011 Biosimilars and Follow-On Biologics Americas conference, February 28 - March 2, 2011 which covered the new abbreviated pathway for biosimilars and other related issues. The purpose of this study is to provide an overview of the U.S. abbreviated biosimilars pathway, a comparison of the abbreviated pathways for biosimilars and small molecule generics, an overview of biosimilars in other countries, an overview of some key trends that affect the biosimilars market, and intellectual property considerations. This study includes content from interviews conducted with key opinion leaders (KOLs) and company executives.

Table of Contents

2011 Biosimilars and Follow-On Biologics Americas Conference: The Frost & Sullivan PerspectiveBiosimilars and Follow-On Biologics Americas: The Frost & Sullivan PerspectiveMarket Insight




Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.